Capricor Therapeutics is trading at $9.55, down 5.02%, after an investor-law-firm announcement publicized a securities-fraud class action and September 28, 2026 lead-plaintiff deadline.
- The complaint alleges undisclosed risks involving Deramiocel’s statistical analysis plan and FDA approval prospects.
- Broader pressure also comes from biotechnology weakness and hawkish Federal Reserve messaging.
- The lawsuit is the clearest company-specific catalyst.